Previous studies suggested that the sphingosine kinase-1 (SPHK1) is a proposed regulator of breast cancer chemoresistance62,63, and that cisplatin-resistant NSCLC cells overexpressed SphK162. Here, SPHK1 is linked to breast carcinoma.